Get the Stockscreener App
22.02
3.43%
0.73
After Hours:
22.06
0.04
+0.18%
Pulse Biosciences Inc stock is traded at $22.02, with a volume of 206.90K.
It is up +3.43% in the last 24 hours and up +14.63% over the past month.
Pulse Biosciences Inc is a novel bioelectric medicine company committed to health innovation using its patented Nano-Pulse Stimulation technology, a revolutionary energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. NPS technology, also referred to as Nanosecond Pulsed Field Ablation (nsPFA) technology delivers nanosecond pulses of electrical energy to nonthermally clear cells while sparing adjacent noncellular tissue.
See More
Previous Close:
$21.29
Open:
$21.36
24h Volume:
206.90K
Relative Volume:
0.64
Market Cap:
$1.50B
Revenue:
$350.00K
Net Income/Loss:
$-72.78M
P/E Ratio:
-20.39
EPS:
-1.08
Net Cash Flow:
$-54.46M
1W Performance:
-2.18%
1M Performance:
+14.63%
6M Performance:
+28.85%
1Y Performance:
+38.93%
1-Day Range:
$21.36
$22.29
1-Week Range:
$20.55
$23.18
52-Week Range:
$12.56
$26.30
Pulse Biosciences Inc Stock (PLSE) Company Profile
Name
Pulse Biosciences Inc
Sector
Industry
Phone
510-906-4600
Address
3957 POINT EDEN WAY, HAYWARD, CA
Compare PLSE vs ISRG, BDX, ALC, MDLN, RMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PLSE
Pulse Biosciences Inc
|
22.02 | 1.45B | 350.00K | -72.78M | -54.46M | -1.08 |
ISRG
Intuitive Surgical Inc
|
469.98 | 167.61B | 10.06B | 2.88B | 2.49B | 7.876 |
BDX
Becton Dickinson Co
|
158.27 | 44.35B | 21.92B | 1.76B | 2.63B | 6.1223 |
ALC
Alcon Inc
|
75.26 | 36.19B | 10.40B | 980.00M | 1.61B | 1.9749 |
MDLN
Medline Inc
|
42.67 | 34.11B | 28.43B | 1.16B | 1.26B | 1.4457 |
RMD
Resmed Inc
|
226.31 | 33.24B | 5.40B | 1.49B | 1.78B | 10.12 |
Pulse Biosciences Inc Stock (PLSE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-30-26 | Initiated | Mizuho | Outperform |
| Jul-07-25 | Initiated | Oppenheimer | Outperform |
| Jul-27-21 | Initiated | Stephens | Overweight |
| Mar-11-21 | Initiated | Maxim Group | Buy |
| Jan-26-21 | Reiterated | H.C. Wainwright | Buy |
| May-12-20 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Feb-14-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Feb-25-19 | Initiated | H.C. Wainwright | Buy |
View All
Pulse Biosciences Inc Stock (PLSE) Latest News
Stock Analysis: Is Pulse Biosciences Inc exposed to currency risks2026 Short Interest & Risk Managed Trade Strategies - baoquankhu1.vn
(PLSE) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Pulse Biosciences to accelerate Pulse Cardiac Catheter Ablation System - MSN
Assessing Pulse Biosciences (PLSE) Valuation After The nPulse Cardiac Catheter Ablation Pivot - Sahm
Pulse Biosciences Touts 96% 12-Month Rhythm Control, Targets Q2 Start for U.S. AF IDE Study - Yahoo Finance
PLSE Stock Price, Quote & Chart | PULSE BIOSCIENCES INC (NASDAQ:PLSE) - ChartMill
What's Going With Pulse Biosciences Stock On Monday? - MSN
Pulse Biosciences targets CE mark submission in 2026 as nPulse platform advances clinical milestones - MSN
Pulse Biosciences at Oppenheimer Conference: Promising AF Ablation Results By Investing.com - Investing.com Canada
Pulse Biosciences (NASDAQ:PLSE) Stock Price Passes Above Fifty Day Moving AverageWhat's Next? - MarketBeat
Pulse Biosciences shifts focus to cardiac catheter program By Investing.com - Investing.com South Africa
Pulse Biosciences (PLSE) Is Up 14.8% After Refocusing On nPulse AFib Catheter PlatformHas The Bull Case Changed? - simplywall.st
Pulse Biosciences Announces Organizational Realignment to Accelerate Cardiac Catheter Program After Exceptional AFib Clinical Results - Minichart
Pulse Biosciences Realigns Strategy Around nPulse AFib Platform - TipRanks
Pulse Biosciences (PLSE) realigns strategy around nPulse AFib catheter program - Stock Titan
Pulse Biosciences Announces Strategic Alignment to Accelerate Cardiac Catheter Program Following Exceptional Long-Term AFib Clinical Data - BioSpace
Pulse Biosciences Announces Strategic Alignment to Accelerate Cardiac Catheter Program - marketscreener.com
Pulse Biosciences (PLSE) Prioritizes nPulse Cardiac Catheter Dev - GuruFocus
Pulse Biosciences shifts focus to cardiac catheter program - Investing.com
Is Pulse Biosciences’ (PLSE) Thyroid Cancer Feasibility Study a Prelude to a Broader Platform Strategy? - Yahoo Finance
A Look At Pulse Biosciences (PLSE) Valuation As Thyroid Cancer Feasibility Study Begins - Yahoo Finance
Pulse Biosciences enrolls first patients in thyroid cancer study - Investing.com Nigeria
Is Pulse Biosciences (PLSE) Pricing Make Sense After Recent Volatility And DCF Estimate Gap - simplywall.st
Responsive Playbooks and the PLSE Inflection - Stock Traders Daily
A Look At Pulse Biosciences (PLSE) Valuation After Recent Share Price Swings - Sahm
Pulse Biosciences enrolls first patients in thyroid cancer study By Investing.com - Investing.com Canada
Pulse Biosciences Launches Thyroid Cancer Feasibility Study - TipRanks
Pulse Biosciences, Inc. Announces First Enrollments in Feasibilit - The National Law Review
Pulse Biosciences, Inc. Announces First Enrollments in Feasibility Study for the Treatment of Malignant Thyroid Tumors with nPulse™ Technology - The Joplin Globe
Pulse Biosciences, Inc. Announces First Enrollments in Feasibility Study for the Treatment of Malignant Thyroid Tumors With NPulse Technology - 富途牛牛
Pulse Biosciences (NASDAQ:PLSE) Trading 8% HigherWhat's Next? - MarketBeat
Breakout Move: Can Pulse Biosciences Inc continue delivering strong returnsMarket Volume Summary & AI Forecast for Swing Trade Picks - baoquankhu1.vn
Pulse Biosciences Announces Long-Term Clinical Data for nPulse Vybrance Percutaneous Electrode System in Benign Thyroid Nodule Ablation 71314 - Minichart
Pulse Biosciences (PLSE) Reports Promising Long-Term Outcomes fo - GuruFocus
Pulse Biosciences Earnings Call: Data Strength Vs. Cash Burn - TipRanks
Pulse Biosciences Announces Clinical Data From nPulse Vybrance System First-In-Human Clinical Durability Study of Benign Thyroid Nodule Ablation - Investing News Network
Pulse Biosciences Reports Durable Thyroid Nodule Ablation Results - TipRanks
Pulse Biosciences (PLSE) reports 74% benign thyroid nodule reduction in nsPFA study - Stock Titan
Pulse Biosciences Announces Clinical Data From nPulse™ Vybrance™ System First-In-Human Clinical Durability Study of Benign Thyroid Nodule Ablation - Business Wire
Why Pulse Biosciences Inc. stock could be next big winnerEarnings Recap Summary & Fast Entry and Exit Trade Plans - Naître et grandir
How strong is Pulse Biosciences Inc. (6L8) stock earnings growthDividend Hike & Low Volatility Stock Recommendations - Naître et grandir
Pulse Biosciences' nPulse Vybrance System to be Featured in Multiple Presentations at the North American Society for Interventional Thyroidology Meeting - Investing News Network
A Look At Pulse Biosciences (PLSE) Valuation After Recent Share Price Momentum - Sahm
Pulse Biosciences to Present at the Oppenheimer 36th Annual Healthcare MedTech & Services Conference - The Joplin Globe
Pulse Biosciences at TD Cowen Conference: NSPFA Technology Shines - Investing.com
FinancialContentPulse Biosciences’ nPulse™ Vybrance™ System to be Featured in Multiple Presentations at the North American Society for Interventional Thyroidology Meeting - FinancialContent
PLSE Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Pulse Biosciences (NASDAQ:PLSE) Stock Passes Above 50 Day Moving AverageShould You Sell? - MarketBeat
Pulse Biosciences Inc Stock (PLSE) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.95%
0.04%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):